Kane Biotech Inc

KNE.V

Not Compliant
Exchange
Sector
Headquarters
Group
Canadian Ventures Exchange
Healthcare
Canada

Kane Biotech Inc is not Shariah Compliant because it fails the financial ratios.

6.65%

Impure Income*

$0.000

Purification*

-

Zakat*

Financials

Market cap Group
Analysts' Rating
Price Target (Mean)
Total Analysts
Revenue Growth
#N/A%
Operating Margin
Net Profit Margin
Quick Ratio
Current Ratio
EPS Growth

Shariah Compliance

  • Updated on July 21, 2026
Debt
29.87%
✓
Non-Compliant Assets
✓
Impure Income
6.65%
✗

AAOIFI Rulebook:

  • Non-compliant Liabilities (like Interest-based Debt) < 30% of Market cap
  • Non-compliant Assets (like Interest-based Investments) < 30% of Market cap
  • Impure Revenues (incl. Interest Income) < 5% of Total Revenues

Source: AAOIFI SS21

Debt
16.66%
✓
Impure Income
6.65%
✗

S&P Sharia Rulebook:

  • Interest-based Debt < 33% of 36-mo avg. Market cap
  • Impure Revenues (incl. Interest Income) < 5% of Total Revenues

Source: S&P Shariah Methodology

Debt
17.01%
✓
Impure Income
6.65%
✗

Dow Jones Islamic Market (DJIM) Rulebook:

  • Interest-based Debt < 33% of 24-mo avg. Market cap
  • Impure Revenues (incl. Interest Income) < 5% of Total Revenues

Source: DJIM Methodology

Debt
100%
✗
Cash
21.82%
✓
Cash & AR
23.44%
✓
Impure Income
6.65%
✗

FTSE Shariah Rulebook:

  • Interest-based Debt < 33.33% of Total Assets
  • Cash and interest-bearing items < 33.33% of Total Assets
  • Accounts receivable and cash < 50% of Total Assets
  • Impure Revenues (incl. Interest Income) < 5% of Total Revenues

Source: FTSE RUSSELL

Debt
100%
✗
Cash
21.82%
✓
Cash & AR
23.44%
✓
Impure Income
6.65%
✗

MSCI Islamic Rulebook:

  • Interest-based Debt < 33.33% of Total Assets
  • Cash and interest-bearing items < 33.33% of Total Assets
  • Accounts receivable and cash < 33.33% of Total Assets
  • Impure Revenues (incl. Interest Income) < 5% of Total Revenues

Source: MSCI Islamic Indexes

Impure Income Breakdown

-
-
Interest Income
6.65%

Note on Purification and Zakat:

  • Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly). 
  • If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
  • For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them. 

Company Profile

Kane Biotech Inc. is a Canada-based biotechnology company, which is engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company’s segments include Animal health, and Human health. It has a portfolio of technologies, intellectual property (patents, patents pending and trademarks) and products developed by the Company’s own biofilm research and acquired from research institutions. DispersinB, coactiv+TM, coactiv+, DermaKBTM, DermaKB BiofilmTM and revyveTM are trademarks of Kane Biotech. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. The Company’s other biofilm disruption technology is DispersinB. DispersinB is a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine (PNAG). DispersinB cleaves PNAG, inhibiting bacterial adhesion and disperses the biofilm.